In a newly revealed study, scientists have captured the first high-resolution 3D structure of a critical malaria parasite protein. Researchers believe this discovery may pave the way for significantly improved anti-malarial treatments.

LB Pharmaceuticals is seeking $228 million through an IPO on the Nasdaq, hoping to become the first biotech to go public since February. The New York-based firm plans to build on medicines that have long been used to treat schizophrenia, aiming to put a modern spin on an established therapy.